Search
Flecainide
go.drugbank.com/drugs/DB01195ApprovedInvestigationalWithdrawn[A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. … [L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.[L8875]
Synonyms: N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamideProducts: FLECAINIDE EG, TAMBOCOR (TABLET 100 MG)Magnesium citrate
go.drugbank.com/drugs/DB11110ApprovedInvestigational[T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. … [L2831] It is also considered as an active ingredient in over-the-counter products.[L1113]
Mixtures: Cal-mag Tablet, PCP 100 KitProducts: MAGGZİUM 400 MG ORAL ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 20 ADET, MAGGZİUM 400 MG ORAL ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 100 ADETPerindopril
go.drugbank.com/drugs/DB00790ApprovedInvestigationalIt is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration.
Mixtures: Triveram 20 mg/5 mg/5 mg Filmtabletten, Triveram 20 mg/10 mg/5 mg FilmtablettenCategories: Agents Acting on the Renin-Angiotensin SystemSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults.
Categories: Drugs Used in Benign Prostatic HypertrophyProducts: SILODOSINA EG, URIEF TABLETS 4 MGRopinirole
go.drugbank.com/drugs/DB00268ApprovedInvestigationalIn 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome [A174547]. … In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous
Products: ROPINIROLO EG, ROPINIROLO EG STADAInfluenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB14444ApprovedInvestigationalWithdrawnInactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Synonyms: Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated), Influenza a Virus A/california/7/2009(h1n1)-like Antigen (Propiolactone Inactivated)Everolimus
go.drugbank.com/drugs/DB01590ApprovedInvestigationalIn a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein. … It is currently used as an immunosuppressant to prevent rejection of organ transplants.
Products: EVEROLIMUS EG, EVEROLIMUS DR. REDDY'SGlycine
go.drugbank.com/drugs/DB00145ApprovedInvestigationalNutraceuticalVet approvedIt is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.
Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 2000 ML, POLİNUTHREE EN-1000 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 2000 MLProducts: GLICINA 1.5% SOLUCION DE IRRIGACION, GLICINA IRRIGACION 1.5% M/VFilgrastim
go.drugbank.com/drugs/DB00099ApprovedInvestigationalIt has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in _E. Coli_. … Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood.
Products: ZARZIO® 30 MU/0.5 ML SOLUCION INYECTABLE O PARA PERFUSION EN JERINGA PRECARGADA, NEUKINE 300 MCG/1.0 MLGranisetron
go.drugbank.com/drugs/DB00889ApprovedInvestigationalA serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Products: GRANI-DENK 1 MG/ ML- AMPOLLA DE 1 ML, TİGRON 3 MG/3 ML İ.V. ENJEKSİYONLUK ÇÖZELTİ, 100 ADET